EPCCS Council Already at the second Council meeting, we shift gears from making plans to taking action and bringing the support of the European Primary Cardiovascular Care Community to a higher level.
ACC 2018 Treatment with alirocumab on top of high-intensity statins lowered MACE by 15% in patients with recent ACS in the ODYSSEY OUTCOMES trial and was associated with a lower rate of all-cause death.
ACC 2018 In the digital mSToPS trial using patient-generated data, a wearable ECG patch improved the rate of AF diagnosis at 1 year compared to routine care.
ACC 2018 In post-MI patients with a low LVEF, WCD reduced total mortality in the immediate post-MI period (<90 days), but not sudden cardiac death.
ACC 2018 Treatment with canakinumab reduced MACE+ in patients with CKD in the CANTOS trial, with a stronger reduction in those who achieved on-treatment hsCRP<2 mg/mL compared to >2 mg/mL.
In a data-driven cluster analysis of 6 variables in adult patients with newly diagnosed diabetes, 5 categories of patients were identified with different characteristics and risks of complications.
Overweight and obese individuals have a significantly increased long-term risk for CVD morbidity, and a similar or shorter total longevity, compared with individuals with a normal BMI.
A genetic predisposition to higher childhood BMI was associated with an increased risk of type 2 diabetes, coronary artery disease, and cardio-metabolic traits in adult life.
Complex long-term medication for CV diseases adversely affects various aspects of every-day life of patients, irrespective of whether they adhere to their treatment regimens or not.
Presentation held during the EPCCS Council 2017 aimed to provide an update on the role of primary care in CV risk management in different countries
Lifestyle importantly contributes to preventable morbidity and mortality. This EPCCS guidance document outlines the presented evidence on ingredients of successful behaviour change strategies and motivational interviewing, as well as which CV risk behaviours and clinical outcomes may be improved with various types of strategies.
In patients with ischemic stroke ≥ 65 years, diabetes is associated with a higher risk of mortality, recurrent events, HF and hospitalisations.